chatfield pharmaceuticals limited Company Information
Company Number
01003809
Website
http://genesis-pharma.comRegistered Address
2 leman street, london, E1W 9US
Industry
Manufacture of basic pharmaceutical products
Telephone
02073704664
Next Accounts Due
43 days late
Group Structure
View All
Shareholders
david louis charles solomon 63%
jane celia frances soloman 37%
chatfield pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of CHATFIELD PHARMACEUTICALS LIMITED at £480.1k based on a Turnover of £401.6k and 1.2x industry multiple (adjusted for size and gross margin).
chatfield pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of CHATFIELD PHARMACEUTICALS LIMITED at £0 based on an EBITDA of £-57.8k and a 5.52x industry multiple (adjusted for size and gross margin).
chatfield pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of CHATFIELD PHARMACEUTICALS LIMITED at £364.5k based on Net Assets of £143.1k and 2.55x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Chatfield Pharmaceuticals Limited Overview
Chatfield Pharmaceuticals Limited is a live company located in london, E1W 9US with a Companies House number of 01003809. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in March 1971, it's largest shareholder is david louis charles solomon with a 63% stake. Chatfield Pharmaceuticals Limited is a mature, micro sized company, Pomanda has estimated its turnover at £401.6k with low growth in recent years.
Upgrade for unlimited company reports & a free credit check
Chatfield Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded Chatfield Pharmaceuticals Limited a 0.5 rating. We use a traffic light system to show it exceeds the industry average on 0 measures and has 9 areas for improvement. Company Health Check FAQs
0 Strong
2 Regular
9 Weak
Size
annual sales of £401.6k, make it smaller than the average company (£30.7m)
- Chatfield Pharmaceuticals Limited
£30.7m - Industry AVG
Growth
3 year (CAGR) sales growth of 1%, show it is growing at a slower rate (3.6%)
- Chatfield Pharmaceuticals Limited
3.6% - Industry AVG
Production
with a gross margin of 38.4%, this company has a comparable cost of product (38.4%)
- Chatfield Pharmaceuticals Limited
38.4% - Industry AVG
Profitability
an operating margin of -14.7% make it less profitable than the average company (6.5%)
- Chatfield Pharmaceuticals Limited
6.5% - Industry AVG
Employees
with 2 employees, this is below the industry average (135)
- Chatfield Pharmaceuticals Limited
135 - Industry AVG
Pay Structure
on an average salary of £58.3k, the company has an equivalent pay structure (£58.3k)
- Chatfield Pharmaceuticals Limited
£58.3k - Industry AVG
Efficiency
resulting in sales per employee of £200.8k, this is less efficient (£277.9k)
- Chatfield Pharmaceuticals Limited
£277.9k - Industry AVG
Debtor Days
it gets paid by customers after 80 days, this is later than average (56 days)
- Chatfield Pharmaceuticals Limited
56 days - Industry AVG
Creditor Days
its suppliers are paid after 3 days, this is quicker than average (40 days)
- Chatfield Pharmaceuticals Limited
40 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Chatfield Pharmaceuticals Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 2 weeks, this is less cash available to meet short term requirements (12 weeks)
2 weeks - Chatfield Pharmaceuticals Limited
12 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 82.4%, this is a higher level of debt than the average (46.2%)
82.4% - Chatfield Pharmaceuticals Limited
46.2% - Industry AVG
CHATFIELD PHARMACEUTICALS LIMITED financials
Chatfield Pharmaceuticals Limited's latest turnover from December 2022 is estimated at £401.6 thousand and the company has net assets of £143.1 thousand. According to their latest financial statements, we estimate that Chatfield Pharmaceuticals Limited has 2 employees and maintains cash reserves of £27.7 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Sep 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | ||||||||||||||
Other Income Or Grants | ||||||||||||||
Cost Of Sales | ||||||||||||||
Gross Profit | ||||||||||||||
Admin Expenses | ||||||||||||||
Operating Profit | ||||||||||||||
Interest Payable | ||||||||||||||
Interest Receivable | ||||||||||||||
Pre-Tax Profit | ||||||||||||||
Tax | ||||||||||||||
Profit After Tax | ||||||||||||||
Dividends Paid | ||||||||||||||
Retained Profit | ||||||||||||||
Employee Costs | ||||||||||||||
Number Of Employees | 1 | 2 | 2 | 2 | 5 | |||||||||
EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Sep 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 1,726 | 1,514 | 2,350 | 3,458 | 546 | 1,167 | 3,415 | 7,274 | 10,834 | 9,015 | 4,039 | 7,259 | 14,451 | 23,247 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 897,665 | 897,665 | 897,665 | 897,665 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 1,726 | 1,514 | 2,350 | 3,458 | 546 | 1,167 | 3,415 | 7,274 | 10,834 | 9,015 | 901,704 | 904,924 | 912,116 | 920,912 |
Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 739,496 | 1,599,150 |
Trade Debtors | 88,764 | 74,733 | 82,693 | 0 | 0 | 0 | 0 | 4,691 | 3,704,398 | 2,568,233 | 601,378 | 1,892,508 | 1,327,933 | 1,393,005 |
Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Misc Debtors | 694,983 | 757,920 | 710,133 | 435,371 | 405,545 | 372,676 | 382,767 | 3,771,105 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash | 27,731 | 34,339 | 29,920 | 276,986 | 60,522 | 190,071 | 195,815 | 165,526 | 510,881 | 123,312 | 28,026 | 64,216 | 282,399 | 193,653 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 811,478 | 866,992 | 822,746 | 712,357 | 466,067 | 562,747 | 578,582 | 3,941,322 | 4,215,279 | 2,691,545 | 629,404 | 1,956,724 | 2,349,828 | 3,185,808 |
total assets | 813,204 | 868,506 | 825,096 | 715,815 | 466,613 | 563,914 | 581,997 | 3,948,596 | 4,226,113 | 2,700,560 | 1,531,108 | 2,861,648 | 3,261,944 | 4,106,720 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 2,484 | 3,120 | 4,918 | 4,238 | 4,388 | 3,713 | 3,024 | 1,634 | 2,477,039 | 1,188,589 | 164,455 | 1,508,953 | 1,477,709 | 2,237,013 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 667,294 | 664,032 | 545,482 | 466,888 | 473,451 | 576,322 | 577,919 | 3,254,357 | 0 | 0 | 0 | 0 | 0 | 0 |
total current liabilities | 669,778 | 667,152 | 550,400 | 471,126 | 477,839 | 580,035 | 580,943 | 3,255,991 | 2,477,039 | 1,188,589 | 164,455 | 1,508,953 | 1,477,709 | 2,237,013 |
loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
provisions | 328 | 379 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 328 | 379 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total liabilities | 670,106 | 667,531 | 550,400 | 471,126 | 477,839 | 580,035 | 580,943 | 3,255,991 | 2,477,039 | 1,188,589 | 164,455 | 1,508,953 | 1,477,709 | 2,237,013 |
net assets | 143,098 | 200,975 | 274,696 | 244,689 | -11,226 | -16,121 | 1,054 | 692,605 | 1,749,074 | 1,511,971 | 1,366,653 | 1,352,695 | 1,784,235 | 1,869,707 |
total shareholders funds | 143,098 | 200,975 | 274,696 | 244,689 | -11,226 | -16,121 | 1,054 | 692,605 | 1,749,074 | 1,511,971 | 1,366,653 | 1,352,695 | 1,784,235 | 1,869,707 |
Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Sep 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | ||||||||||||||
Operating Profit | ||||||||||||||
Depreciation | 1,120 | 836 | 1,108 | 432 | 621 | 2,248 | 4,946 | 4,958 | 4,687 | 3,996 | 3,220 | 7,551 | 19,290 | 18,923 |
Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax | ||||||||||||||
Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -739,496 | -859,654 | 1,599,150 |
Debtors | -48,906 | 39,827 | 357,455 | 29,826 | 32,869 | -10,091 | -3,393,029 | 71,398 | 1,136,165 | 1,966,855 | -1,291,130 | 564,575 | -65,072 | 1,393,005 |
Creditors | -636 | -1,798 | 680 | -150 | 675 | 689 | 1,390 | -2,475,405 | 1,288,450 | 1,024,134 | -1,344,498 | 31,244 | -759,304 | 2,237,013 |
Accruals and Deferred Income | 3,262 | 118,550 | 78,594 | -6,563 | -102,871 | -1,597 | -2,676,438 | 3,254,357 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes & Provisions | -51 | 379 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | ||||||||||||||
Investing Activities | ||||||||||||||
capital expenditure | ||||||||||||||
Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -897,665 | 0 | 0 | 0 | 897,665 |
cash flow from investments | ||||||||||||||
Financing Activities | ||||||||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
share issue | ||||||||||||||
interest | ||||||||||||||
cash flow from financing | ||||||||||||||
cash and cash equivalents | ||||||||||||||
cash | -6,608 | 4,419 | -247,066 | 216,464 | -129,549 | -5,744 | 30,289 | -345,355 | 387,569 | 95,286 | -36,190 | -218,183 | 88,746 | 193,653 |
overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | -6,608 | 4,419 | -247,066 | 216,464 | -129,549 | -5,744 | 30,289 | -345,355 | 387,569 | 95,286 | -36,190 | -218,183 | 88,746 | 193,653 |
chatfield pharmaceuticals limited Credit Report and Business Information
Chatfield Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for chatfield pharmaceuticals limited by selecting its closest rivals, whether from the MANUFACTURING sector, other micro companies, companies in E1W area or any other competitors across 12 key performance metrics.
chatfield pharmaceuticals limited Ownership
CHATFIELD PHARMACEUTICALS LIMITED group structure
Chatfield Pharmaceuticals Limited has no subsidiary companies.
Ultimate parent company
CHATFIELD PHARMACEUTICALS LIMITED
01003809
chatfield pharmaceuticals limited directors
Chatfield Pharmaceuticals Limited currently has 2 directors. The longest serving directors include Mr David Solomon (Jul 2000) and Mrs. Charmian Solomon (Jul 2000).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mr David Solomon | United Kingdom | 54 years | Jul 2000 | - | Director |
Mrs. Charmian Solomon | 88 years | Jul 2000 | - | Director |
P&L
December 2022turnover
401.6k
+10%
operating profit
-59k
0%
gross margin
38.5%
-4.63%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
143.1k
-0.29%
total assets
813.2k
-0.06%
cash
27.7k
-0.19%
net assets
Total assets minus all liabilities
chatfield pharmaceuticals limited company details
company number
01003809
Type
Private limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
incorporation date
March 1971
age
53
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
December 2022
previous names
N/A
accountant
GRAVITA 111 LLP
auditor
-
address
2 leman street, london, E1W 9US
Bank
-
Legal Advisor
-
chatfield pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to chatfield pharmaceuticals limited.
chatfield pharmaceuticals limited Companies House Filings - See Documents
date | description | view/download |
---|